Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical mechanisms without original data or systematic review methodology.
PubMed 41516357 · doi:10.3390/ijms27010485
What was done
Narrative review synthesizing existing preclinical and clinical literature on the mitochondrial actions of nicotinamide riboside (NR) and berberine (BBR), examining their individual signaling pathways, points of convergence, and potential as a combinatorial therapy.
What was found
The abstract reports qualitative mechanistic descriptions and contains no quantitative findings or effect sizes. It details that NR elevates cellular NAD+ levels, activates sirtuins, promotes PGC-1α-driven mitochondrial biogenesis, and triggers the mitochondrial unfolded protein response. In parallel, BBR activates AMPK, interacts with respiratory complex I, reduces reactive oxygen species, and stimulates mitophagy. The two compounds converge on shared downstream pathways governing redox balance, metabolic flexibility, and immunometabolic control.
Why it matters
Synthesizes complementary bioenergetic mechanisms to propose rational combination strategies targeting mitochondrial dysfunction across aging and metabolic disorders.
Limits
Contains no original human or experimental data and did not use a systematic review methodology. The abstract specifically notes heterogeneous clinical outcomes across existing human trials and a persistent lack of robust, validated biomarkers for assessing mitochondrial function in clinical settings.
Cited by
- supports Berberine activates the AMP-activated protein kinase (AMPK) pathway.